Soluble fibrin monomer complexes (SFMC) were determined in patients with septic abortion (body temperatures of more than 39 °C and/or chills without apparent signs of endotoxic shock), with infected abortion, with non-infected abortion and with normal pregnancies. Quantitative gel filtration (4% agarose) of β-alanine precipitated plasma samples yielded the relative (percent of total fibrinogen content) and absolute (mg/l00 ml plasma) amount of SFMC. The relative (5.5 ± 1.4%, mean ± SD) and absolute (21.5 ± 8.6 mg/l00 ml) amount of SFMC was significantly increased in patients with septic abortion compared to patients with normal pregnancies or non-infected abortion (p < 0.001). Patients with infected abortion already revealed increased levels of SFMC (4.3 ± 1.2%, 14.2 ± 6.8 mg/l00 ml) though their platelet count was still unaltered (infected abortion: 221 ± 47 × 103 platelets/mm3; septic abortion: 99 ± 36 × 103 platelets/mm3). The use of heparin in patients with septic abortion resulted in a decrease in SFMC. Chain characterization of SFMC frequently revealed a slight degradation of the α-chains probably due to fibrinolytic activity in vivo; γ-γ dimers representing inter-molecular covalent bindings were not observed. The findings are in agreement with our former assumption that patients with septic abortion have a pronounced state of hypercoagulability.

Keywords:
Hypercoagulability, Septic abortion, Soluble fibrin monomer complexes, Gel filtration, Chain characterization
This content is only available via PDF.
© 1976 S. Karger AG, Basel
1976
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.